NCT04905277View on ClinicalTrials.gov

Atenolol for the Prevention of Osteoporosis (APO)

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

420

Participants

Timeline

Start Date

July 27, 2021

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Healthy

Interventions

DRUG

Atenolol 50 MG

50 mg Atenolol daily

DRUG

Placebo

one placebo daily

Trial Locations (3)

10032

Columbia University Irving Medical Center, New York

55905

Mayo Clinic, Rochester

04074

MaineHealth, Scarborough

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Columbia University

OTHER

collaborator

MaineHealth

OTHER

collaborator

University of California, San Francisco

OTHER

lead

Sundeep Khosla, M.D.

OTHER

NCT04905277 - Atenolol for the Prevention of Osteoporosis (APO) | Biotech Hunter | Biotech Hunter